Arcus Biosciences and partner Gilead announced a Phase 3 failure for anti‑TIGIT antibody domvanalimab in upper gastrointestinal cancers and said they will stop related phase III programs; an independent data monitoring committee recommended halting for futility. Arcus subsequently disclosed a strategic reorientation, dropping some domvanalimab trials and reallocating resources toward alternative programs. The setback adds to mounting negative data for TIGIT as a target in oncology and has prompted Arcus to narrow its pipeline focus and prioritize assets with clearer paths to differentiation. Partner dynamics with Gilead and internal R&D restructuring are underway; investors will track upcoming pipeline updates and any asset‑sale or reprioritization moves. For readers: TIGIT is an immune‑checkpoint target that had been pursued to boost anti‑PD‑1 responses.